CryoPort (NASDAQ:CYRX) Director Sells $358,424.16 in Stock

CryoPort, Inc. (NASDAQ:CYRX) Director Ramkumar Mandalam sold 23,214 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $15.44, for a total transaction of $358,424.16. Following the completion of the transaction, the director owned 67,894 shares in the company, valued at $1,048,283.36. This represents a 25.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CryoPort Stock Down 1.4%

CryoPort stock traded down $0.22 during mid-day trading on Monday, hitting $15.48. The company had a trading volume of 573,254 shares, compared to its average volume of 912,079. The stock has a market cap of $780.19 million, a price-to-earnings ratio of 11.47 and a beta of 1.90. CryoPort, Inc. has a 1 year low of $6.16 and a 1 year high of $16.73. The business has a fifty day moving average of $11.89 and a 200 day moving average of $10.17.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $47.80 million during the quarter, compared to analysts’ expectations of $44.86 million. CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. Equities analysts anticipate that CryoPort, Inc. will post -0.85 earnings per share for the current year.

Hedge Funds Weigh In On CryoPort

Hedge funds have recently modified their holdings of the business. Basepoint Wealth LLC purchased a new position in shares of CryoPort during the fourth quarter worth approximately $34,000. Tower Research Capital LLC TRC grew its position in shares of CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after acquiring an additional 4,375 shares during the last quarter. AlphaQuest LLC purchased a new position in shares of CryoPort during the third quarter worth approximately $79,000. Quadrature Capital Ltd purchased a new position in shares of CryoPort during the fourth quarter worth approximately $97,000. Finally, Corient Private Wealth LLC purchased a new position in shares of CryoPort during the fourth quarter worth approximately $113,000. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on CYRX. KeyCorp increased their price target on shares of CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Weiss Ratings upgraded shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. Needham & Company LLC increased their price target on shares of CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Wall Street Zen upgraded shares of CryoPort from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Craig Hallum raised their target price on shares of CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.11.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.